Thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in type 2 diabetic patients: An intravascular ultrasound study

Journal of Cardiology

Volumn 45, Issue 4, 2005, Pages 139-147

  Takagi, Tsutomu ^a   Yamamuro, Atsushi ^b   Tamita, Koichi ^b   Katayama, Minako ^b   Morioka, Shigefumi ^b  

^a Takagi Cardiology Clinic   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

Diabetes mellitus (thiazolidinedione); Intravascular ultrasound; Restenosis; Stent

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; PIOGLITAZONE; PROBUCOL; STATINE DERIVATIVE; SULFONYLUREA DERIVATIVE; TICLOPIDINE; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT;

ADULT; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG EFFECT; FEMALE; HUMAN; IMPLANTATION; INTRAVASCULAR ULTRASOUND; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; TREATMENT OUTCOME; CORONARY BLOOD VESSEL; DIABETIC ANGIOPATHY; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; HYPERPLASIA; INTIMA; MIDDLE AGED; PATHOLOGY; STENT;

AGED; CORONARY RESTENOSIS; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPERPLASIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; STENTS; THIAZOLIDINEDIONES; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 19444368068     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB: Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome. Circulation 1999; 100: 1872-1878
2. Kornowski R, Mintz GS, Kent KM, Pichard AD, Satler LF, Bucher TA, Hong MK, Popma JJ, Leon MB: Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: A serial intravascular ultrasound study. Circulation 1997; 95: 1366-1369
3. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, Pichard AD, Kent KM, Satler LF, Wu H, Popma JJ, Leon MB: The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32: 584-589
4. Lee SG, Lee CW, Hong MK, Park HK, Kim JJ, Park SW, Park SJ: Predictors of diffuse-type in-stent restenosis after coronary stent implantation. Catheter Cardiovasc Interv 1999; 47: 406-409
5. Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, Yoshida K: Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study. J Am Coll Cardiol 2000; 36: 1529-1535
6. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Morioka S, Akasaka T, Yoshida K: Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 2002; 89: 318-322
7. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K, Shiratori K, Morioka S, Yoshikawa J: Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: An intravascular ultrasound scanning study. Am Heart J 2003; 146: E5
8. Reimers B, Moussa I, Akiyama T, Tucci G, Ferraro M, Martini G, Blengino S, Di Mario C, Colombo A: Long-term clinical follow-up after successful repeat percutaneous intervention for stent restenosis. J Am Coll Cardiol 1997; 30: 186-192
9. vom Dahl J, Radke PW, Haager PK, Koch KC, Kastrau F, Reffelmann T, Janssens U, Hanrath P, Klues HG: Clinical and angiographic predictors of recurrent restenosis after percutaneous transluminal rotational atherectomy for treatment of diffuse in-stent restenosis. Am J Cardiol 1999; 83: 862-867
10. Bossi I, Klersy C, Black AJ, Cortina R, Choussat R, Cassagneau B, Jordan C, Laborde JC, Laurent JP, Bernies M, Fajadet J, Marco J: In-stent restenosis: Long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. J Am Coll Cardiol 2000; 35: 1569-1576
11. Morino Y, Limpijankit T, Honda Y, Lansky AJ, Waksman R, Bonneau HN, Yock PG, Mintz GS, Fitzgerald PJ: Late vascular response to repeat stenting for in-stent restenosis with and without radiation: An intravascular ultrasound volumetric analysis. Circulation 2002; 105: 2465-2468
12. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, Leon MB: Patterns and mechanisms of in-stent restenosis: A serial intravascular ultrasound study. Circulation 1996; 94: 1247-1254
13. Dussaillant GR, Mintz GS, Pichard AD, Kent KM, Satler LF, Popma JJ, Wong SC, Leon MB: Small stent size and intimal hyperplasia contribute to restenosis: A volumetric intravascular ultrasound analysis. J Am Coll Cardiol 1995; 26: 720-724
14. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE: Neointimal tissue response at site of coronary stenting in human: Macroscopic, histological, and immunohistochemical analyses. Circulation 1998; 98: 224-233
15. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R: Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99: 44-52
16. Chung IM, Gold HK, Schwartz SM, Ikari Y, Reidy MA, Wight TN: Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol 2002; 40: 2072-2081
17. Kastrati A, Mehilli J, Dirschinger J, Pache J, Ulm K, Schuhlen H, Seyfarth M, Schmitt C, Blasini R, Neumann FJ, Schomig A: Restenosis after coronary placement of various stent types. Am J Cardiol 2001; 87: 34-39
18. Prati F, Di Mario C, Moussa I, Reimers B, Mallus MT, Parma A, Lioy E, Colombo A: In-stent neointimal proliferation correlates with the amount of residual plaque burden outside the stent: An intravascular ultrasound study. Circulation 1999; 99: 1011-1014
19. Endo A, Hirayama H, Yoshida O, Arakawa T, Akima T, Yamada T, Nanasato M: Arterial remodeling influences the development of intimal hyperplasia after stent implantation. J Am Coll Cardiol 2001; 37: 70-75
20. Sahara M, Kirigaya H, Oikawa Y, Yajima J, Ogasawara K, Satoh H, Nagashima K, Hara H, Nakatsu Y, Aizawa T: Arterial remodeling patterns before intervention predict diffuse in-stent restenosis: An intravascular ultrasound study. J Am Coll Cardiol 2003; 42: 1731-1738
21. Orie NN, Zidek W, Tepel M: Increased intracellular generation of reactive oxygen species in mononuclear leukocytes from patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetic 2000; 108: 175-180
22. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue tumor necrosis factor and interluekin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745-E751
23. Pickup JC, Mattock MB, Chusney GD, Burt D: NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interluekin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292
24. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE: Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43: 104-109
25. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H: Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: A potential factor predisposing to thrombosis and its persistence. Circulation 1998; 97: 2213-2221
26. Moreno PR, Fallon JT, Murcia AM, Leon MN, Simosa H, Fuster V, Palacios IF: Tissue characteristics of restenosis after percutaneous transluminal coronary angioplasty in diabetic patients. J Am Coll Cardiol 1999; 34: 1045-1049
27. Kawano M, Koshikawa T, Kanzaki T, Morisaki N, Saito Y, Yoshida S: Diabetes mellitus induces accelerated growth of aortic smooth muscle cells: Association with overexpression of PDGF beta-receptors. Eur J Clin Invest 1993; 23: 84-90
28. Kanzaki T, Shinomiya M, Ueda S, Morisaki N, Saito Y. Yoshida S: Enhanced arterial intimal thickening after balloon catheter injury in diabetic animals accompanied by PDGF beta-receptor overexpression of aortic media. Eur J Clin Invest 1994; 24: 377-381
29. Iwamoto Y, Kosaka K, Kuzuya T. Akanuma Y, Shigeta Y, Kaneko T: Effects of troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19: 151-156
30. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL, for the Pioglitazone 001 Study Group: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000; 23: 1605-1611
31. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA: Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24: 710-719
32. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98: 1897-1905
33. Shinohara E, Kihara S, Ouchi N, Funahashi T, Nakamura T, Yamashita S, Kameda-Takemura K, Matsuzawa Y: Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats. Atherosclerosis 1998; 136: 275-279
34. Yasunari K, Kohno M, Kano H, Yokokawa K, Minami M, Yoshikawa J: Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells. Circ Res 1997; 81: 953-962
35. Yoshimoto T, Naruse M, Shizume H, Naruse K, Tanabe A, Tanaka M, Tago K, Irie K, Muraki T, Demura H, Zardi L: Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 1999; 145: 333-340
36. Igarashi M, Hirata A, Yamaguchi H, Tsuchiya H, Ohnuma H, Tominaga M, Daimon M, Kalo T: Characterization of an inhibitory effect of pioglitazone in balloon-injured vascular smooth muscle cell growth. Metabolism 2001; 50: 955-962
37. de Dios ST, Bruemmer D, Dilley RJ, Ivey ME, Jennings GL, Law RE, Little PJ: Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 2003; 107: 2548-2550
38. Aizawa Y, Kawabe J, Hasebe N, Takehara N, Kikuchi K: Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 2001; 104: 455-460
39. Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, Usui M, Kitamoto S, Ichiki T, Takeshita A: Antiinflammatory and antiarterioslerotic effects of pioglitazone. Hypertension 2002; 40: 687-693
40. Fonseca VA, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquet TR, Graveline J, Fink LM: Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Daibetes Complications 1998; 12: 181-186
41. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684
42. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K: Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26: 2493-2499
43. Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, Lim SK, Lee HC, Cha BS: Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27: 2654-2660